Epithelial Ovarian Cancer

Complete remission was obtained using stereotactic radiotherapy to the brain lesions, followed by platinum-based chemotherapy and maintenance therapy with bevacizumab and olaparib...Their role in this setting remains emerging and primarily supported by limited case reports and small series. Further studies are required to better define their role.

Collectively, these findings identify M. restricta as a pro-tumourigenic fungus in EOC and uncover a previously unrecognised fungal-immune axis that promotes tumour progression. This study provides new insight into the oncogenic role of tumour-resident fungi and highlights the M. restricta EV-JAK2/STAT3 axis as a potential therapeutic target for immune modulation.

Although Gdf15-modulated AhR signaling initially mediates anticancer effects, the prolonged interplay between Gdf15 and AhR is linked to impaired NK cell surveillance. The prediction of adverse outcomes via the Gdf15-AhR axis provides new insights into the malignant evolution of the tumor-NK cell niche and the environmental susceptibility of EOC progression.

The hsa-miR-429/ZNF662/NUPR1/p53 pathway axis critically regulates EOC pathogenesis. ZNF662 represents a promising diagnostic biomarker and therapeutic target for EOC.

Elevated serum CA125, HE4, ROMA, and CPH-I are associated with unfavorable surgical outcomes, platinum resistance, and poor prognosis in advanced EOC. ROMA and CPH-I, in particular, may serve as valuable adjunctive tools for preoperative prediction of cytoreductive surgery outcomes, while all four biomarkers contribute to risk stratification for platinum sensitivity and disease progression. These findings support the potential role of combined serum biomarker assessment in guiding individualized treatment strategies for patients with advanced EOC.

P2, N=63, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial primary completion date: Sep 2025 --> Jun 2026

ADC target expression varied substantially by ovarian cancer histotype. In paired specimens, cognate ADC exposure was associated with a directional decrease in target expression, suggesting possible therapy-associated antigen modulation. These preliminary findings support longitudinal biomarker reassessment to guide subsequent ADC selection and trial eligibility.

P1/2, N=36, Recruiting, Beijing Biotech

P1/2, N=65, Not yet recruiting, Blue Earth Diagnostics Ireland Limited | N=27 --> 65

P1/2, N=25, Active, not recruiting, Alexander B Olawaiye, MD | Recruiting --> Active, not recruiting | N=70 --> 25 | Trial completion date: Dec 2027 --> Dec 2030 | Trial primary completion date: Dec 2025 --> May 2030

Its use continues to evolve, particularly in the context of cervical and ovarian cancers. Ongoing trials will clarify its role in oncologic outcomes.

Olaparib-resistant OVCAR8 and A2780 cells are established by exposure to increasing concentrations of Olaparib, and pharmacological inhibition or knockdown of GLUT1 restores Olaparib sensitivity, with synergistic effects confirmed in patient-derived organoids and xenograft models. Mechanistically, GLUT1 suppression reduces lactate accumulation, subsequently impairing tumor proliferation and DNA repair capacity through downregulation of the DNA repair protein MRE11. These findings establish lactate as a key mediator of PARPi resistance and propose targeting lactate metabolism as a promising combination strategy to improve PARPi efficacy in advanced ovarian cancer.